Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.

Nurix Therapeutics, a US-based oncology therapy developer backed by pharmaceutical firm Celgene, priced its shares at $19 on Thursday and raised $209m when it went public on Friday. The company issued 11 million shares on the Nasdaq Global Market and is trading under the ticker symbol NRIX. Nurix had initially planned to sell 8.8 million…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.